293 related articles for article (PubMed ID: 33456567)
1. KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia.
Zhang C; Shen L; Zhu Y; Xu R; Deng Z; Liu X; Ding Y; Wang C; Shi Y; Bei L; Wei D; Thorne RF; Zhang XD; Yu L; Chen S
Theranostics; 2021; 11(6):2691-2705. PubMed ID: 33456567
[No Abstract] [Full Text] [Related]
2. Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.
Sheng Y; Ji Z; Zhao H; Wang J; Cheng C; Xu W; Wang X; He Y; Liu K; Li L; Voeltzel T; Maguer-Satta V; Gao WQ; Zhu HH
Cell Prolif; 2019 Jul; 52(4):e12611. PubMed ID: 31054182
[TBL] [Abstract][Full Text] [Related]
3. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
4. Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia.
Li W; Ji M; Lu F; Pang Y; Dong X; Zhang J; Li P; Ye J; Zang S; Ma D; Ji C
Cell Death Dis; 2018 Aug; 9(9):855. PubMed ID: 30154435
[TBL] [Abstract][Full Text] [Related]
5. Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.
Feng H; Fu Y; Cui Z; Zhou M; Zhang L; Gao Z; Ma S; Chen C
Br J Haematol; 2023 Sep; 202(6):1178-1191. PubMed ID: 37469124
[TBL] [Abstract][Full Text] [Related]
6. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
7. TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis.
Zhang H; Wang Y; Yang H; Huang Z; Wang X; Feng W
Oncol Rep; 2021 Feb; 45(2):557-568. PubMed ID: 33416164
[TBL] [Abstract][Full Text] [Related]
8. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Jin B; Wang C; Shen Y; Pan J
Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
10. WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.
Montano G; Vidovic K; Palladino C; Cesaro E; Sodaro G; Quintarelli C; De Angelis B; Errichiello S; Pane F; Izzo P; Grosso M; Gullberg U; Costanzo P
Oncotarget; 2015 Sep; 6(29):28223-37. PubMed ID: 26320177
[TBL] [Abstract][Full Text] [Related]
11. Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor.
Zhu Y; Lu L; Qiao C; Shan Y; Li H; Qian S; Hong M; Zhao H; Li J; Yang Z; Chen Y
Oncogene; 2018 May; 37(21):2837-2849. PubMed ID: 29511345
[TBL] [Abstract][Full Text] [Related]
12. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
14. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia.
Wen F; Cao YX; Luo ZY; Liao P; Lu ZW
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):1-8. PubMed ID: 30366670
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of
Deng Y; Li X; Feng J; Zhang X
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
[TBL] [Abstract][Full Text] [Related]
17. LncRNA OIP5-AS1 Promotes the Autophagy-Related Imatinib Resistance in Chronic Myeloid Leukemia Cells by Regulating miR-30e-5p/ATG12 Axis.
Dai H; Wang J; Huang Z; Zhang H; Wang X; Li Q; Feng W
Technol Cancer Res Treat; 2021; 20():15330338211052150. PubMed ID: 34723728
[No Abstract] [Full Text] [Related]
18. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance.
Nie ZY; Yao M; Yang Z; Yang L; Liu XJ; Yu J; Ma Y; Zhang N; Zhang XY; Liu MH; Jiang LL; Luo JM
J Exp Clin Cancer Res; 2020 Jan; 39(1):17. PubMed ID: 31952546
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells.
Zhang J; Zhang M; Liang Y; Liu M; Huang Z
Hematology; 2022 Dec; 27(1):43-52. PubMed ID: 34957936
[No Abstract] [Full Text] [Related]
20. GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.
Han SH; Korm S; Han YG; Choi SY; Kim SH; Chung HJ; Park K; Kim JY; Myung K; Lee JY; Kim H; Kim DW
Autophagy; 2019 Dec; 15(12):2076-2090. PubMed ID: 30929559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
